Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
About this item
Full title
Author / Creator
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has been developed by Menarini Group under the brand name Orserdu®. Elacestrant showed anticancer activity both in vitro and in vivo in ER+ HER2-positive breast cancer models. The present review delebrate...
Alternative Titles
Full title
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2814527606
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2814527606
Other Identifiers
ISSN
1559-131X,1357-0560
E-ISSN
1559-131X
DOI
10.1007/s12032-023-02045-2
